Surgical Treatment of Peri-implantitis Defects

The Efficacy of Electrolysis Decontamination with or Without Leukocyteplatelet Rich Fibrin (L-PRF) in the Surgical Treatment of Peri-implantitis Defects: a Randomized Controlled Trial

The aim of this study is to evaluate the efficacy of implant surface decontamination using electrolysis cleaning system. And to evaluate the adjunctive use of L-PRF in promoting soft tissue healing and long-term stability of the peri-implant marginal bone in the surgical treatment of peri-implantitis.

Research design

• Prospective, in which participants will be recruited and then followed up throughout a specified period of time.
• Randomized, parallel designed, concurrent controlled trial with participants randomly allocated to either control or test groups.
• Single-blinded as the outcome accessors will be blinded to the intervention.

Materials and Methods:

Patients attending Dubai Dental Hospital and requiring treatment of peri-implantitis will be invited to take part in this randomized controlled trial based on the following inclusion and exclusion criteria:

Inclusion criteria:

• Aged 18 or over.
• Require treatment of peri-implantitis (defined as the presence of bleeding and/or suppuration on gentle probing, probing depths of ≥ 6 mm, presence of bone loss beyond crestal bone level changes resulting from initial bone remodeling).
• Screw retained implant crown.
• Good compliance and commitment to attend follow-up review appointments.
• Willing to provide informed consent.

Exclusion criteria

• History of surgical therapy of peri-implantitis.
• Peri-implant defects indicated for regenerative procedure (i.e. contained bony defect).
• Cement retained implant crown.
• Systemic/local antibiotics during the previous 6 months.
• Bone metabolic disease and/or taking medications that affect bone metabolism.
• History of malignancy, radiotherapy or chemotherapy.
• Pregnant or lactating women.
• Smokers

The study will be conducted following the ethical standards of the Declaration of Helsinki in 1975, as revised in 2013 and the CONSORT statement will be used as a guideline in reporting this study.

Randomization, allocation concealment and blinding:

The participants will be randomly allocated to three equally sized groups using computer-generated numbers:

Control group (C): Conventional open flap debridement Test group 1 (T1): Open flap debridement using (GalvoSurge® - Straumann) Test group 2 (T2): Open flap debridement using (GalvoSurge® - Straumann) combined with L-PRF application

Inclusion Criteria:

• Aged 18 or over.
• Require treatment of peri-implantitis (defined as the presence of bleeding and/or suppuration on gentle probing, probing depths of ≥ 6 mm, presence of bone loss beyond crestal bone level changes resulting from initial bone remodeling).
• Screw retained implant crown.
• Good compliance and commitment to attend follow-up review appointments.
• Willing to provide informed consent.

Exclusion Criteria:

• History of surgical therapy of peri-implantitis.
• Peri-implant defects indicated for regenerative procedure (i.e. contained bony defect).
• Cement retained implant crown.
• Systemic/local antibiotics during the previous 6 months.
• Bone metabolic disease and/or taking medications that affect bone metabolism.
• History of malignancy, radiotherapy or chemotherapy.
• Pregnant or lactating women.
• Smokers